Filing Details

Accession Number:
0001209191-20-012484
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-25 16:36:40
Reporting Period:
2020-02-21
Accepted Time:
2020-02-25 16:36:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1446847 Ironwood Pharmaceuticals Inc IRWD Pharmaceutical Preparations (2834) 043404176
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1781117 Kelly Macdonald C/O Ironwood Pharmaceuticals, Inc.
100 Summer Street, Suite 2300
Boston MA 02110
Chief Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Disposition 2020-02-21 302 $11.63 86,725 No 4 S Direct
Class A Common Stock Disposition 2020-02-21 504 $11.63 86,221 No 4 S Direct
Class A Common Stock Disposition 2020-02-21 303 $11.63 85,918 No 4 S Direct
Class A Common Stock Disposition 2020-02-21 793 $11.63 85,125 No 4 S Direct
Class A Common Stock Disposition 2020-02-21 303 $11.63 84,822 No 4 S Direct
Class A Common Stock Disposition 2020-02-21 1,695 $11.63 83,127 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The reporting person acquired 460 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2019.
  4. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
  5. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2017.
  6. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
  7. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2018.
  8. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.